Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oxford BioTherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Total Funding

$21.6 M


£2.1 M

FY, 2018

CreditSafe Score

Score changed on Feb 25, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017FY, 2018
Cost of goods sold82.0K125.3K117.2K157.4K480.4K438.6K
Gross profit345.3K176.7K272.1K1.5M2.6M
Gross profit margin, %80.8%60.1%63.4%76.0%85.5%
Operating expense total1.1M1.3M1.5M2.0M8.1M8.8M7.7M
Depreciation and amortization139.8K
EBITDA margin, %-438.1%-380.6%-322.4%-202.8%-66.0%
EBIT margin, %-170.4%-462.0%-400.2%-328.6%-207.2%-69.3%-312.8%
Interest expense1.0M
Pre tax profit(773.4K)(1.4M)(1.4M)(1.8M)(6.9M)(7.0M)(3.4M)(7.6M)
Income tax expense227.0K158.5K187.6K165.2K1.2M964.4K1.1M(1.1M)
Net Income(546.5K)(1.3M)(1.2M)(1.6M)(5.6M)(6.0M)(2.3M)(6.5M)

Footer menu